| |
With a 60+ year legacy of excellence in bioscience manufacturing, Puerto Rico is a hub for groundbreaking discoveries in the region & beyond. Local talent, tax benefits & the island's decades of expertise fuel companies like CytoImmune & OcyonBio. Learn more. 
|
|
Today’s Big NewsJan 31, 2024 |
|
Stability and particle formation are key variables across the lifecycle. New instruments that improve measurement are transforming testing and becoming necessary. Download this essential reading now for biopharma companies that want to understand how particle detection is evolving and the value new technologies provide across the lifecycle. 
|
|
| By Eric Sagonowsky Biogen is discontinuing its first Alzheimer's disease therapy, Aduhelm, after walking a rocky path. The company is taking a $60 million charge, halting sales and terminating a confirmatory trial. |
|
|
|
By Max Bayer Novavax says 12% of its workforce was cut as part of a second wave of layoffs announced at the end of 2023, bringing last year’s full-year staff reduction to about 30%. |
By Nick Paul Taylor Novartis’ anti-TIM-3 antibody has flunked a phase 3 blood cancer trial, prompting the Swiss drugmaker to pull the drug candidate from its pipeline. The failed study was the biggest test to date of an immuno-oncology target into which a who’s who of leading drug developers have pumped money. |
By Andrea Park In a giant leap for medtech-kind, a robotic surgery system is now en route to the International Space Station. |
|
This whitepaper reveals how to strategically scale processes, offering developers flexibility from 1,000L to an industry-leading 5,000L in a single-use bioreactor. Meticulous optimization ensures high-quality drug products, while expert-led parameter fine-tuning guarantees consistent growth across scales. Explore how suspension cells lead the way,providing a robust and adaptable manufacturing platform for gene therapy breakthroughs. .png)
|
|
By Fraiser Kansteiner After charting a series of sales increases in 2023, Teva’s largely made good on the promise of its new CEO’s “Pivot to Growth” campaign. With group revenues on the up-and-up, it’s all about maintaining momentum in the years to come, the company’s chief executive Richard Francis said in an interview. |
By Conor Hale The agency's approval coincided with Boston Scientific's latest earnings report, which posted 14.9% growth for last quarter and a 12.3% gain for the full year of 2023. |
By Nick Paul Taylor GSK is moving to ease worries about the looming loss of exclusivity on its HIV blockbuster, setting out plans to launch at least 12 major products and deliver more than 38 billion pounds ($48 billion) in risk-adjusted sales by 2031. |
By Fraiser Kansteiner Lawyers for AstraZeneca are set to tussle with the U.S. Department of Justice in a federal court. The British drugmaker aims to challenge the legality of the drug pricing provisions put in place under 2022’s Inflation Reduction Act, which will allow Medicare to haggle over the prices of some of the costliest drugs it covers starting in 2026. |
By Gabrielle Masson After a phase 2 flop late last year, allogeneic T-cell company Atara Biotherapeutics is laying off 25% of staff and sending its chief medical officer out the door. |
By Andrea Park BD and Techcyte’s offering will launch first in Europe in the first half of this year, since Techcyte’s system already has CE mark approval on the continent. |
Fierce podcasts Don’t miss an episode |
| While it’s a known fact that women, on average, live longer than men, a recent report unveils a nuanced reality—women also spend more of their lives grappling with poor health. This week on “The Top Line,” Ayla Ellison, editor-in-chief of Fierce Healthcare and Life Sciences, explores the root causes behind this disparity and the multifacted nature of the women’s health gap. |
|
|---|
|
|
|
This white paper explains how Resilience utilizes a Stage-Gate approach to technology transfer and biomanufacturing. Built on proven methods used across industries, the Stage-Gate approach mitigates risk while shortening cycle times throughout the project lifecycle. Download now. 
|
|
Whitepaper Discover how to effectively classify highly potent APIs and the steps required to develop containment protocols and manufacturing processes that are both safe and efficient. Sponsored by: Catalent |
eBook This e-book explores 7 factors that are critical to the success of emerging biopharma companies, whether they plan to out-license, partner, or launch & commercialize products. It’s an essential resource for emerging companies with products in all stages of development.
Presented by Blue Matter, strategic consultants in the life sciences |
| |
|
